Company Insights

SINT supplier relationships

Explore interactive graphBrowse insights index
SINT supplier relationship map

SINTX Technologies: supplier relationships that enable scale — and the supplier risk investors must price

Sintx Technologies (NASDAQ: SINT) manufactures and commercializes silicon nitride ceramics and SiN/PEEK compounds for medical implants and device applications, monetizing through product sales, licensing of IP, contract manufacturing partnerships, and selective M&A to acquire complementary surgical assets. Revenue today is small relative to market cap, so growth depends on commercial-scale manufacturing partnerships, patent-driven differentiation, and capital markets access. For an operator or investor, the central question is whether SINTX can convert technical lead into volume revenue without being bottlenecked by supplier concentration or short-term purchasing arrangements. For deeper supplier mapping and monitoring visit https://nullexposure.com/.

How SINTX is positioned operationally and what that means for suppliers

SINTX is an advanced materials company selling to the medical device market; it develops ceramic chemistry and partners with third parties to produce commercial volumes of specialty compounds and implants. The company’s operating model demonstrates two structural characteristics:

  • Short-term contracting posture: SINTX discloses that it presently has no long-term supply contracts with many suppliers, which signals a purchasing stance that is flexible but exposes the company to execution risk if suppliers reprice or decline capacity (company disclosure referenced in SINTX filings; confidence signal drawn from company-level text).
  • Supplier concentration and materiality: SINTX depends on a limited number of third‑party suppliers for key raw materials and formulations, a condition it defines as material to operations and capable of harming production if a supplier relationship fails (company disclosure; higher-confidence company-level signal).

These constraints translate into a simple investor rubric: commercial partnerships and capacity agreements are the growth enablers; supplier concentration and short contracting windows are the principal operational risks.

What every public relationship tells investors

Below I summarize each relationship reported in public sources; each one is a discrete, actionable data point for procurement, commercial, and investment diligence.

1) Evonik — MarketScreener report on supply agreement (FY2025)

SINTX signed a supply agreement with Evonik to manufacture a silicon nitride–PEEK (SiN/PEEK) compound intended for AI-assisted, 3D‑printed patient‑specific implants, giving SINTX a route to commercial-scale material supply. According to MarketScreener’s December 2025 coverage, the deal positions Evonik to produce to SINTX specifications (MarketScreener, FY2025 — https://www.marketscreener.com/news/sintx-technologies-signs-supply-agreement-with-evonik-to-manufacture-silicon-nitride-peek-compound-f-ce7d51d8da8af12d).

2) KCSA Strategic Communications — Barchart notice for investor meetings (FY2025)

KCSA is acting as the communications contact for one‑on‑one investor scheduling ahead of a Sidoti conference, signaling that SINTX uses specialized investor relations channels to coordinate management access (Barchart event notice, FY2025 — https://www.barchart.com/story/news/36507987/sintx-technologies-to-participate-in-sidoti-company-investor-conference).

3) Sidoti & Company — Presentation at Year‑End Virtual Investor Conference (FY2025)

SINTX management presented at Sidoti & Company’s Year‑End Virtual Investor Conference on December 10–11, 2025, reflecting active investor outreach and a strategy to broaden institutional awareness (Barchart release summarizing the Sidoti event, FY2025 — https://www.barchart.com/story/news/36507987/sintx-technologies-to-participate-in-sidoti-company-investor-conference).

4) Prodways — Joint webinar on 3D printing and ceramic slurries (FY2024)

Prodways and SINTX jointly hosted a webinar where Prodways provided 3D printing platform expertise while SINTX contributed ceramic slurry chemistry, indicating active co‑development of additive manufacturing workflows for ceramics (GlobeNewswire release, Sept 2024 — https://www.globenewswire.com/fr/news-release/2024/09/20/2949635/30038/en/Prodways-and-SINTX-Announce-Joint-Webinar-Stay-Ahead-of-the-Curve-Innovations-in-Ceramic-Manufacturing-The-Role-of-3D-Printing.html).

5) Evonik — Intellectia.ai report expanding on production role (FY2026)

Public coverage notes Evonik will leverage commercial‑scale capability to produce SINTX’s SiN/PEEK compound to SINTX specifications, enabling immediate manufacturing of the AI‑designed implants — a functional confirmation of the Evonik supply pathway (Intellectia.ai summary, FY2026 — https://intellectia.ai/en/stock/SINT/news).

6) H.C. Wainwright & Co. — Placement agent for warrant exercise proceeds (FY2025)

H.C. Wainwright acted as exclusive placement agent in connection with a successful warrant exercise that raised gross proceeds for SINTX, showing reliance on boutique investment banks for capital raises (GlobeNewswire press release, Sept 8, 2025 — https://www.globenewswire.com/news-release/2025/09/08/3146027/30038/en/SINTX-Technologies-Announces-Successful-Exercise-of-Warrants-for-3-8-Million-Gross-Proceeds.html).

7) Evonik — MarketScreener mention tied to a patent news release (FY2025)

MarketScreener referenced the Evonik supply agreement in coverage of SINTX’s U.S. patent allowance, linking product IP news with commercial supply execution (MarketScreener coverage, Dec 2025 — https://www.marketscreener.com/news/sintx-strengthens-infection-prevention-portfolio-with-newly-allowed-u-s-patent-covering-30-billion-ce7d5adcd981f325).

8) Evonik — Additional MarketScreener repetition (FY2025)

A separate MarketScreener item reiterated the Evonik supply agreement alongside patent news, underscoring how multiple outlets combined IP and supply developments in December 2025 (MarketScreener replication, FY2025 — https://www.marketscreener.com/news/sintx-strengthens-infection-prevention-portfolio-with-newly-allowed-u-s-patent-covering-30-billion-ce7d5adcd981fe24).

9) Evonik Corporation — VoxelMatters technology report (FY2026)

VoxelMatters reported that Evonik Corporation will produce SINTX’s special SiN/PEEK material at scale for additively manufactured, patient‑specific implants, emphasizing commercial production capability (VoxelMatters article, FY2026 — https://www.voxelmatters.com/sintx-technologies-signs-with-evonik-to-produce-sin-peek-compound-for-3d-printed-implants/).

10) Evonik Corporation — TradingView notice of the supply agreement (FY2025)

A TradingView note summarized the December 1, 2025 announcement that SINTX signed a supply agreement with Evonik Corporation to produce its SiN/PEEK compound, reinforcing broad press coverage of the deal (TradingView release, FY2025 — https://www.tradingview.com/news/tradingview:9735da70e492b:0-sintx-technologies-inc-signs-supply-agreement-with-evonik-corporation/).

11) SiNAPTIC Holdings, LLC — Acquisition of surgical assets and IP (FY2025)

SINTX executed a definitive agreement to acquire SiNAPTIC’s surgical business assets and IP to expand into the foot & ankle fusion market, signaling a move to integrate downstream surgical product capability (GlobeNewswire announcement, June 24, 2025 — https://www.globenewswire.com/news-release/2025/06/24/3104226/30038/en/SINTX-Technologies-Acquires-SiNAPTIC-Surgical-Assets-and-IP-to-Expand-into-1-3B-Foot-and-Ankle-Fusion-Market.html).

12) ThroughCo Communications — Media contact information in study release (FY2025)

ThroughCo Communications served as SINTX’s listed media and business inquiry contact in a press release highlighting a landmark antiviral study for silicon nitride, illustrating outsourced press strategy (SahmCapital/ThroughCo release, Sept 3, 2025 — https://www.sahmcapital.com/news/content/sintx-technologies-publishes-landmark-study-demonstrating-broad-spectrum-antiviral-activity-of-silicon-nitride-2025-09-03).

13) HC Wainwright — ATM agreement SEC filing reference (FY2025)

MarketScreener’s chronology notes a previous at‑the‑market (ATM) agreement with HC Wainwright referenced in an SEC filing, reinforcing that SINTX uses equity programs and placement agents for liquidity needs (MarketScreener SEC coverage, FY2025 — https://www.marketscreener.com/news/sintx-strengthens-infection-prevention-portfolio-with-newly-allowed-u-s-patent-covering-30-billion-ce7d5adcd981f325).

14) ThroughCo Communications — Media contacts in warrant exercise release (FY2025)

The successful warrant exercise press release lists ThroughCo Communications for media inquiries, repeating the use of the same PR firm across financing and scientific announcements (GlobeNewswire warrant exercise release, Sept 2025 — https://www.globenewswire.com/news-release/2025/09/08/3146027/30038/en/SINTX-Technologies-Announces-Successful-Exercise-of-Warrants-for-3-8-Million-Gross-Proceeds.html).

15) GlobeNewswire — Corporate announcement channel for investor presentation (FY2025)

GlobeNewswire distributed the investor conference presentation announcement that management would appear at Sidoti, demonstrating SINTX’s use of mainstream press distribution for investor communications (Barchart/GlobeNewswire citation, Dec 8, 2025 — https://www.barchart.com/story/news/36507987/sintx-technologies-to-participate-in-sidoti-company-investor-conference).

For ongoing supplier monitoring and a consolidated view, see https://nullexposure.com/ — the platform is built for investor-grade supplier tracking.

What this relationship map implies for value creation and risk

  • Evonik stands out as a strategic production partner: the Evonik supply agreement is the highest-leverage commercial development in the public record because it enables commercial-scale manufacturing of SiN/PEEK — a prerequisite for meaningful implant revenue. That operational de‑risking is the primary near-term value driver.
  • M&A and IP consolidation are active levers: the SiNAPTIC acquisition shows SINTX is integrating surgical capability and IP to move from materials toward device economics, which could expand margins if clinical adoption follows.
  • Capital markets access is necessary: repeated use of HC Wainwright and warrant/ATM mechanisms indicates SINTX finances growth partly through equity programs; that is standard for small-cap medical technology companies but dilutive if repeated without revenue scaling.
  • Supplier concentration and short contract horizons are the principal operational risks: company disclosures confirm reliance on a small set of suppliers and the absence of binding long-term supply contracts, which elevates execution risk until multi-year supply agreements or internal capacity are in place.

If you want a compact monitoring sheet or automated alerts for SINTX supplier developments, start tracking the Evonik supply progression, SiNAPTIC integration milestones, and fundraising announcements in real time at https://nullexposure.com/.

Bottom line for investors and operators

Evonik’s production agreement materially raises the probability SINTX can scale manufacturing; the SiNAPTIC acquisition advances product-market fit; and capital raises are funding that path. However, supplier concentration and a short-term contracting stance remain structural risks until long-term capacity commitments are secured or SINTX brings more volume production in-house. Track technical milestones, Evonik production timelines, integration milestones from SiNAPTIC, and any long-form supply contracts as the decisive next catalysts.

For an investor-grade supplier risk profile and continuous monitoring of SINTX’s counterparties, visit https://nullexposure.com/ and subscribe for alerts.